Streetbeat News

Products Services

AMZN

DOX

TU

Amdocs has signed a multi-year managed services agreement with TELUS to migrate their on-premise monetization operations to Amazon Web Services (AWS). This move aims to enhance flexibility, reliability, and scalability for TELUS, allowing them to bring new products to market faster and at reduced costs.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:55 pm

SCSC

ScanSource, Inc. (NASDAQ:SCSC) has acquired Resourcive, a technology advisor specializing in IT sourcing solutions. The acquisition aims to create a new Channel Advisory business, separate from ScanSource's existing Intelisys business. No financial terms were disclosed.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:44 pm

RKLB

Rocket Lab has started installing the largest automated fiber placement (AFP) machine in its Neutron rocket production line. This custom-designed AFP machine will automate the production of the largest carbon composite rocket structures, potentially saving 150,000 manufacturing hours.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:44 pm

DBX

Dropbox, Inc. (NASDAQ:DBX) shares rose after the company reported strong Q2 financial results, beating analyst expectations with earnings of 60 cents per share on revenue of $634.5 million. Total ARR increased to $2.573 billion, and paying users grew to 18.22 million. The company is focusing on improving its core FSS product and investing in AI-powered universal search.

Portfolio Pulse from Erica Kollmann

August 08, 2024 | 9:44 pm

RKLB

Rocket Lab has successfully conducted a hot fire test of its new Archimedes rocket engine, marking a critical milestone towards the first launch of its medium-lift rocket, Neutron.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:43 pm

CTXR

Citius Pharmaceuticals Inc (NASDAQ:CTXR) has received FDA approval for its skin cancer drug Lymphir, a year after an initial rejection. Lymphir is the first FDA-approved product for Citius and targets the interleukin-2 receptor on malignant T-cells and Tregs. The company plans to launch the drug in the U.S. within five months. The approval is based on a phase 3 trial showing a 36% overall response rate. CTXR stock closed lower by 1.76% at $0.88 on Thursday.

Portfolio Pulse from Vandana Singh

August 08, 2024 | 9:41 pm

FIVN

Five9 (NASDAQ:FIVN) announced its acquisition of Acqueon, a real-time revenue execution platform, to enhance its Intelligent CX Platform. The deal is expected to close in the second half of 2024. This strategic move aims to improve AI-driven, omnichannel customer engagement, helping businesses maximize revenue and deliver better customer experiences.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:40 pm

MRIN

Marin Software shares are trading higher after the company announced AI-powered tool enhancements to its integrations with Reddit and X.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:39 pm

ANTX

AN2 Therapeutics shares are trading lower after the company announced the discontinuation of its EBO-301 study following topline results from its Phase 2 part of the study in treatment-refractory patients with MAC lung disease.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:39 pm

ANTX

AN2 Therapeutics announced the discontinuation of its EBO-301 Phase 2/3 study evaluating Epetraborole for treatment-refractory Mycobacterium avium Complex (MAC) lung disease following topline results. The company will shift focus to its internal boron chemistry platform and ongoing pipeline programs. The restructuring and cost savings from discontinuing the study are expected to extend the company's cash runway through 2027.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 9:37 pm